9. Lupin

Gained: 27.09 percent to 529.5 from 416.65

Market Cap: 23,656.38 Crore

Lupin is an India-based pharmaceutical company. The company produces a range of generic and branded formulations and Active Pharmaceutical Ingredients (APIs). The Company’s product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments. The Company’s drug delivery platforms include Bioadhesive/Gastroretentive Extended Release, Laser-Drilled Extended Release, Matrix/Coated Extended Release, Taste Masking Technologies and Improved Bioavailability through Solubilizationand Nano-particle technology. Its APIs products include antibiotics, Antibiotics, ANTI-TB, Cardiovasculars, Central Nervous System, Analegesics and ANTI-GOUT. As on March 31, 2011, the Company had 18 subsidiaries. During the fiscal year ended March 31, 2011, the Company merged Novodigm with its API business.

Lupin is currently traded at 566.15 and previously closed at 573.60. Its 52 week high is 567.00 and 52 week low is 405.40. It is traded with an average volume of 822,982 everyday.